Trial
NCT03245619
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Investigation of GSK3335065 Intravenous (IV) Infusion in Healthy Adults
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Pancreatitis, Acute Necrotizing
Intervention
GSK3335065
Why stopped
The study was terminated as relationship between GSK3335065 and ventricular tachycardia could not be excluded.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-06-16